For OVA-expressing melanoma, CTLA-4 blockade or Treg depletion (with anti-CD25 mAb) showed improvement in tumor control and enhanced induction of OVA-specific CD8+ T cells whereas CTLA-4 mAb application without RF ablation did not mediate the same effects [72]. This evidence concerns the gene CD8A and neoplasm.